Coherus Biosciences | CHRS - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
Baxter International USD 3.69B 723M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Fujifilm JPY 1.26T 57.74B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
Merck USD 26.94B 1.38B 2026-03
Myriad Genetics USD 130.2M 3.6M 2026-03
Pacira USD 108.79M 11.8M 2026-03
Perrigo USD 997.6M 15.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03
Xencor USD 73.46M 22.45M 2026-03
Zoetis USD 2.05B 182M 2026-03